After Its Biggest Drop Ever

1. HIMS faced a 34.53% single-day stock drop, its worst ever. 2. Novo Nordisk terminated its partnership with HIMS, citing 'deceptive marketing.' 3. HIMS plans to continue offering compounded GLP-1 meds despite the split. 4. CEO Dudum claims Novo is under financial strain and attempts margin protection. 5. Growing competition in GLP-1 market presents future opportunities for HIMS.